MDxHealth Launches Equity Offering
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - April 4, 2011 - MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostics company in the field of personalized
cancer treatment, today announced the launch of an equity offering by means of a
private placement to certain investors, with the intention to raise an amount of
approximately ? 6 million. The size of the placement may be increased, however.
The board of directors has cancelled the preferential subscription right of the
existing shareholders in the framework of this transaction.
Kempen & Co and Nomura Code Securities are acting as joint lead managers and
joint bookrunners and ING Belgium acts as co-lead manager for the private
placement, which shall be structured as an accelerated bookbuilding process to
establish the offer price and final size of the placement. The accelerated
bookbuilding process shall start with immediate effect and is expected, barring
unforeseen circumstances to close on April 5, subject to acceleration or
extension of the timetable.
The net proceeds of the private placement will be used, in order of priority
(subject to the size of the placement), to accelerate product development in
line with the new business strategy and to set up a CLIA laboratory and hire a
sales and marketing team in the US.
The new shares will be admitted to listing and will be fungible with the
existing shares on NYSE Euronext Brussels following their issuance and the
publication of the approved listing prospectus. The company has requested the
Financial Services and Markets Authority to suspend its shares from trading on
NYSE Euronext Brussels and NYSE Euronext Amsterdam pending the placement.
Trading in the stock is expected to resume following the publication of the
results of the placement.
The company will announce the results of the offering as soon as possible after
closing of the bookbuilding in a subsequent press release.
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and
commercializes oncology-based molecular diagnostic testing for personalized
medicine. The company's tests are based on proprietary gene methylation
technology and assist physicians with the diagnosis of cancer, prognosis of
recurrence risk, and prediction of response to a specific therapy. MDxHealth
collaborates with leading cancer research center such as Johns Hopkins
University and Memorial Sloan Kettering, and major European academic medical
centers. The company has a number of commercial and collaborative partnerships
with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche,
Merck Serono, Pfizer, and other industry leaders. More information can be found
on the Company website:www.mdxhealth.com or on twitter at the following address
: www.twitter.com/mdxhealth.
For more information:
Dr. Jan Groen, CEO Hans Herklots
MDxHealth Capricorn One
+32 4 364 20 70 +41 79 598 7149
Important information about forward-looking statements
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
Important notice
This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities of MDxHealth, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make such offer,
solicitation or sale. This press release is not an offer of securities for sale
into the United States, Canada, Australia or Japan.
The new shares have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "US Securities Act") and may not be
offered or sold in the United States absent registration or an exemption from
registration. The Company does not intend to register any portion of the placing
in the United States or to conduct a public offering of securities in the United
States.
2011-04-04 Launch ENG:
http://hugin.info/137314/R/1503275/438212.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
[HUG#1503275]
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2011 - 17:45 Uhr
Sprache: Deutsch
News-ID 53140
Anzahl Zeichen: 6044
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MDxHealth Launches Equity Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
